Protocol Ledger

NCT05009082 · Phase III · RECRUITING

Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer

Interventional Phase III clinical trial protocol NCT05009082 sponsored by AGO Study Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-09-13 Enrollment: 970 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05009082
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)970 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05009082
Protocol FieldVerified Registry Value
NCT IdentifierNCT05009082
Consolidated Lead SponsorAGO Study Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment970 participants (ESTIMATED)
Registered Start Date2022-09-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05009082
Hospital Research SiteLocationSite Profile
Universitätsklinikum EssenEssen, GermanyOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI